Marina Chiara Garassino to gamma-Glutamyltransferase
This is a "connection" page, showing publications Marina Chiara Garassino has written about gamma-Glutamyltransferase.
Connection Strength
0.163
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 04; 19(4):521-536.
Score: 0.163
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.